vimarsana.com
Home
Live Updates
Sanofi - Aventis Groupe: Press Release: Fitusiran prophylaxi
Sanofi - Aventis Groupe: Press Release: Fitusiran prophylaxi
Sanofi - Aventis Groupe: Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis
Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis A median annualized bleeding rate
Related Keywords
Israel ,
Tel Aviv ,
Eva Schaefer Jansen ,
Corentine Driancourt ,
Felix Lauscher ,
Nathalie Pham ,
Sally Bain ,
Gili Kenet ,
Priya Nanduri ,
Global Head Of Development ,
International Society On Thrombosis ,
Alnylam Pharmaceutical Inc ,
Nasdaq ,
Euronext ,
International Society ,
Israeli National Hemophilia Center ,
Sheba Medical Center ,
Amalia Biron Thrombosis Research Institute ,
Tel Aviv University ,
Chief Medical ,
On Demand Factor Concentrates ,
Bypassing Agents ,
Breakthrough Bleeds ,
Two Phase ,
Targeting Antithrombin ,
Antithrombin Levels ,
Thrombin Generation ,
Alnylam Pharmaceutical ,
Private Securities Litigation Reform Act ,
Statement Regarding Forward Looking ,
Sanofi ,
Eventis ,
Roupe ,
Dress ,
Release ,
Fitusiran ,
Prophylaxis ,
Educed ,
Leeds ,
People ,
Hemophilia ,
Without ,
Inhibitors ,
Ompared ,
Rior ,
Factor ,
Bypassing ,
Agent ,